Lumos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	13.13	19.61	4.42	5.48	6.7	9.72
Short-Term Investments	25.85	63.07	-	-	-	-
Cash & Short-Term Investments	38.99	82.68	4.42	5.48	6.7	9.72
Cash Growth	-56.14%	1770.10%	-19.30%	-18.29%	-31.03%	-
Accounts Receivable	22.01	21.14	12.76	13.66	11.44	13.82
Other Receivables	-	0.9	0.9	1.61	1.77	1.28
Receivables	22.01	22.04	13.65	15.27	13.21	15.1
Prepaid Expenses	4.63	0.77	0.38	0.84	0.36	0.78
Other Current Assets	-	1.79	2.43	0.02	0.1	-
Total Current Assets	82.13	107.28	20.89	21.6	20.37	25.61
Property, Plant & Equipment	3.16	2.58	2.55	2.95	0.64	0.88
Long-Term Investments	-	4.79	-	-	-	-
Goodwill	18.69	9.03	9.03	9.03	9.03	7.67
Other Intangible Assets	12.51	4.37	0.34	0.68	1.64	1.73
Long-Term Accounts Receivable	9.41	12.61	6.25	2.88	2.47	4.22
Long-Term Deferred Charges	-	1.45	1.5	-	-	-
Other Long-Term Assets	1.73	0.25	0.32	1.58	1.59	1.8
Total Assets	127.63	142.35	40.89	38.72	35.73	41.91
Accounts Payable	1.85	3.32	2.5	1.86	2.08	2.37
Accrued Expenses	23.95	8.39	10.09	8.28	7.19	7.45
Short-Term Debt	-	-	2	2	0.5	1.24
Current Portion of Long-Term Debt	1.11	1.46	-	-	-	-
Current Portion of Leases	0.86	0.74	0.74	0.97	-	-
Current Income Taxes Payable	1.52	1.67	1.63	1.53	0.71	0.43
Current Unearned Revenue	9.3	7.5	7.88	7.48	5.42	6.81
Other Current Liabilities	-	11.41	0.17	0.74	1.03	1.21
Total Current Liabilities	38.61	34.49	24.99	22.85	16.93	19.51
Long-Term Debt	1.95	2.93	-	-	-	2.25
Long-Term Leases	1.28	0.95	1.2	1.43	-	-
Long-Term Unearned Revenue	5.21	3.59	5.07	4.08	3.54	2.91
Long-Term Deferred Tax Liabilities	-	0.3	-	0.29	-	-
Other Long-Term Liabilities	1	0.01	0.22	0.06	0.89	-
Total Liabilities	48.04	42.26	31.48	28.7	21.36	24.67
Common Stock	0	0	0	0	0	0
Additional Paid-In Capital	137.57	130.36	-	-	-	-
Retained Earnings	-56.69	-28.01	11.39	11.93	15.85	17.7
Comprehensive Income & Other	-1.29	-2.27	-1.99	-1.91	-1.49	-0.46
Shareholders' Equity	79.59	100.08	9.4	10.02	14.37	17.24
Total Liabilities & Equity	127.63	142.35	40.89	38.72	35.73	41.91
Total Debt	5.21	6.08	3.93	4.39	0.5	3.49
Net Cash (Debt)	33.78	81.38	0.49	1.09	6.2	6.23
Net Cash Growth	-64.58%	16576.64%	-55.02%	-82.51%	-0.40%	-
Net Cash Per Share	1.17	3.17	0.02	0.05	0.31	0.31
Filing Date Shares Outstanding	29.6	28.67	20	20	20	20
Total Common Shares Outstanding	29.6	28.53	20	20	20	20
Working Capital	43.52	72.79	-4.11	-1.25	3.44	6.1
Book Value Per Share	2.69	3.51	0.47	0.50	0.72	0.86
Tangible Book Value	48.38	86.69	0.03	0.32	3.7	7.84
Tangible Book Value Per Share	1.63	3.04	0.00	0.02	0.18	0.39
Buildings	-	0.2	0.17	0.17	0.18	0.19
Machinery	-	0.65	0.7	0.9	1.1	2.14
Leasehold Improvements	-	0.21	0.19	0.15	0.15	0.15

Updated May 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q